Advertisement

Topics

Latest Endocrinology NewsRSS

07:09 EDT 29th March 2017 | BioPortfolio

Active Pharmaceutical Ingredients API Global Market Forecast To 2022 [Updated: 19052016] Prices from USD $4500

Active Pharmaceutical Ingredients APIs are active substances in a drug intended to achieve pharmacological activity which is having direct effect on diagnosis or treatment of disease. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from natural source. API market is mainly driven by the factors such as patent expiration of blockbuster drugs, increased...

The Rare Neurological Disease Report Now Available

Neurology Reviews® and NORD publish the 3rd annual issue to raise awareness of rare disorders and shorten time to diagnosis..

Elon Musk’s latest target: Brain-computer interfaces

Tech billionaire Elon Musk's new venture is focused on linking brains to computers and developing brain implants that can treat neural disorders.

Thyroid Pharmacist Discusses their Revolutionary Docu-Series “Thyroid Secret”

The Thyroid Secret is a specialized 9-part documentary series designed by leading thyroid pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects of it, besides answering common questions regarding thyroid function. (PRWEB) March 29, 2017 The Thyroid Secret is a specialized 9-part documentary series designed...

Neural Analytics to Present at the 16th Annual Needham Healthcare Conference

Neural Analytics, a medical device company developing and commercializing technology to measure, diagnose and track brain health, announced today that CEO Leo Petrossian, PhD will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 2:00 p.m. ET at the Westin Grand Central in New York, NY. Dr. Petrossian will provide a co...

Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of a novel oral drug

Touch Medical Media Announces Abd Tahrani as Editor-in-Chief of European Endocrinology

GORING-ON-THAMES, England, March 28, 2017 /PRNewswire/ -- Touch Medical Media has named Abd Tahrani, MD as the new Editor-in-Chief of their journal European Endocrinology, a peer reviewed, open access journal dedicated to the publication of topical articles in the endocrinology field.      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO ) Dr. Tahrani w...

Dietary Supplement Enhances Tamoxifen in Treatment of Breast Cancer

SANTA ROSA, Calif., March 28, 2017 /PRNewswire/ --  A peer-reviewed study just published in BMC Complementary and Alternative Medicine demonstrates that the dietary supplement BreastDefend inhibits the growth and proliferation of human breast cancer cells. This is the fourth study to show the effects of BreastDefend -- a botanical-nutrient formula -- against human breast cancer grow...

Optim Partners with HealthSouth Corporation as the Preferred Vendor for the MobileFEES™ System

STURBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Optim LLC, a premier manufacturer of proprietary flexible endoscopes for use in the visual diagnosis of Ear-Nose-and-Throat ("ENT") disorders, announced today it has been chosen by HealthSouth Corporation as the Preferred Vendor by their Therapy Leadership Board for new and replacement equipment used to diagnose and manage swallowing disorders...

Boston Children’s and GE Healthcare Combine to Use AI in Pediatric Imaing

SOURCE Collaboration aims to help doctors interpret pediatric brain images faster and more accurately Targeted tool is intended to help reduce misdiagnosis of brain disorders... Read More →

Boston Children’s and GE Healthcare Combine to Use AI in Pediatric Imaging

SOURCE Collaboration aims to help doctors interpret pediatric brain images faster and more accurately Targeted tool is intended to help reduce misdiagnosis of brain disorders... Read More →

Omeros Corp OMER Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummaryOmeros Corp Omeros discovers, develops and commercializes smallmolecule and protein therapeutics for largemarket and orphan indications targeting inflammation, coagulopathies and central nervous system disorders. The company's pipeline products include Omidria, a phenylephrine and ketorolac injection and its product candidates are intended for the treatment of ophthalmological, arthroscopic...

Primary Immune Deficiency PID Pipeline Review, H1 2017 [Updated: 08032017] Prices from USD $2000

Primary Immune Deficiency PID Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency PID Pipeline Review, H1 2017, provides an overview of the Primary Immune Deficiency PID Genetic Disorders pipeline landscape.Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other he...

Collaboration Announced Between Somnology, Inc. and National Institute of Health

Today, over 70 million in the domestic U.S. have sleep disorders. International health organizations report globally those afflicted with sleep disorders approximate 1 billion. Elliptically, sleep disorders are increasing annually by 9%. Sleep is no longer a benign secondary consideration, but a primary health concern. Sleep disorders impact the y...

Global Thyroid Gland Disorder Treatment Market to Witness Growth, Owing to Increase in Awareness Programs: Technavio

The global thyroid gland disorder treatment market is expected to grow at a CAGR of more than 3% during the forecast period, according to Technavio’s latest market research. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170324005157/en/

Diabetic Macular Edema Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000

Diabetic Macular Edema Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema Metabolic Disorders pipeline landscape.Diabetic macular edema DME occurs when blood vessels in the retina of patients with diabetes begin to leak into the macul...

DiaSorin S.p.A DIA Medical Equipment Deals and Alliances Profile [Updated: 14022017] Prices from USD $250

SummaryDiaSorin S.p.A. DiaSorin is a medical diagnostics company that develops, manufactures and markets in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Radioimmunometry RIA, Enzyme Linked Immunosorbent Assays ELISA and Chemiluminescence CLIA techniques, to enable automatic diagnostic investigation. The company's products find application in the diagnosis ...

Accomplished Business Executive To Take the Helm As CEO of American Association of Clinical Endocrinologists

Paul A. Markowski, CAE, a business executive with three decades of experience in association management for some of the nation’s premier medical organizations, is joining the Jacksonville, Florida-based American Association of Clinical Endocrinologists (AACE) as the organization’s new Chief Executive Officer. This Smart News Release features multimedia....

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy

First Immuno-Oncology agent to receive positive CHMP opinion for the treatment of an advanced form of head and neck cancer Positive opinion based on overall survival benefit demonstrated in the Phase 3 CheckMate -141 trial Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CH...

Secondary Hyperparathyroidism Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000

Secondary Hyperparathyroidism Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism Pipeline Review, H1 2017, provides an overview of the Secondary Hyperparathyroidism Hormonal Disorders pipeline landscape.Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyr...

FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

ROCKLAND, Mass. and NEW YORK, March 23, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and...

Therapeutic Solutions International Inc TSOI Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 24022017] Prices from USD $250

SummaryTherapeutic Solutions International Inc Therapeutic Solutions is a pharmaceutical company that provides supplement products. The company offers three products namely ProJuvenol, TRx and Vital. ProJuvenol consists of antiaging ingredients which helps for a healthy functionality for everyday living and promotes cellular rejuvenation. TRx is developed to increase the testosterone levels. Vital...

Millendo Therapeutics Announces Data Presentations for MLE4901 and ATR-101 at ENDO 2017 and Kisspeptin 2017

-- Oral Late-breaking Presentation: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes -- Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hor

Ascendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3

COPENHAGEN, Denmark, March 23, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will host a conference call and webcast on Monday, April 3 during ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida,...

Degenerative Disc Disease Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000

Degenerative Disc Disease Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease Pipeline Review, H1 2017, provides an overview of the Degenerative Disc Disease Musculoskeletal Disorders pipeline landscape.Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main...

Quick Search
Advertisement
 

review and buy Endocrinology market research data and corporate reports here